Estadístiques de Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
Visites totals
| views | |
|---|---|
| Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 | 50 |
Visites totals per mes
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Barreiro_is_prec.pdf | 39 |
| Barreiro_is_prec.pdf(legacy) | 33 |
Vistes principals per país
| views | |
|---|---|
| United States | 39 |
| Spain | 7 |
| Ireland | 1 |
| Mongolia | 1 |
| Malaysia | 1 |
| Netherlands | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Mountain View | 8 |
| Barcelona | 5 |
| San Ramon | 5 |
| San Diego | 4 |
| Fairfield | 3 |
| Alella | 2 |
| Ann Arbor | 2 |
| Boardman | 2 |
| San Mateo | 2 |
| Seattle | 2 |
| Dublin | 1 |
| Menlo Park | 1 |
| Shah Alam | 1 |
| Sükhbaatar | 1 |